Dr Lal Path Labs Q2FY25 results: Net profit jumps 18% to Rs 129 cr

The company's consolidated net profit increased 18 per cent year-over-year to Rs 129 crore ($15.4 million), increasing for the sixth quarter in a row

Q2 earnings, Q2
The company operates about 300 labs in India.
Reuters
1 min read Last Updated : Oct 23 2024 | 5:16 PM IST

Dr. Lal PathLabs, India's top diagnostics firm by revenue, reported a bigger-than-expected second-quarter profit on Wednesday, driven by continued demand and a rising awareness for health and wellness.

The company's consolidated net profit increased 18 per cent year-over-year to Rs 129 crore ($15.4 million), increasing for the sixth quarter in a row.

That beat analysts' estimates of Rs 126 crore, according to estimates compiled by LSEG.

The company, which operates about 300 labs in India, said the number of samples it tested climbed 10 per cent and that it is building back volumes.

Analysts said awareness regarding health and wellness is rising in the country and, along with Dr. Lal PathLabs' expansion into smaller cities, is boosting demand for medical tests. They also said the company is expected to benefit from price hikes.

However, Dr. Lal PathLabs did not specify if it raised prices of its tests.

The company's revenue from operations increased 10 per cent to Rs 660 crore, beating analysts' estimates of Rs 600 crore.

Rival Metropolis Healthcare is yet to report its September quarter results. 

 

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Dr Lal PathLabsQ2 resultsmedical test

First Published: Oct 23 2024 | 5:16 PM IST

Next Story